Results 151 to 160 of about 2,710 (195)

Use of a multifocal electroretinogram to evaluate the therapeutic effect of a single intravitreal dexamethasone implant, Ozurdex^®, for refractory diabetic macular oedema. [PDF]

Int J Retina Vitreous
Mohammed ARA, Othman MFS, Khairat YM, Abdelrahman AAM.   +3 more
europepmc   +1 more source

Effectiveness of aflibercept, ranibizumab, and Ozurdex for treating diabetic macular edema showing a suboptimal response: A comparative observational study. [PDF]

Taiwan J Ophthalmol
Chassid O, Wiegler KB, Bashir A, Arad D, Hadar G, Sharabi-Nov A, Cohen Y.   +6 more
europepmc   +1 more source

Subconjunctival dexamethasone implant (Ozurdex^®) in the management of refractory Non-Infectious anterior scleritis. [PDF]

J Ophthalmic Inflamm Infect
Ganbold B, Nguyen BT, Hung JH, Mobasserian A, Thng ZX, Ghoraba H, Yavari N, Feky DE, Yasar C, Saengsirinavin AO, Zhang X, Anover FA, Mohammadi SS, Tuong N, Than T, Khatri A, Elaraby O, Akhavanrezayat A, Gupta AS, Yoo WS, Nguyen QD, Or C.   +21 more
europepmc   +1 more source

Back of the Eye Drug Delivery: Advances, Challenges, and Emerging Opportunities for Transformative Therapies. [PDF]

J Ocul Pharmacol Ther
Chauhan A, Kompella U.
europepmc   +1 more source

Intravitreal Corticosteroids in the Management of Refractory Macular Edema in Birdshot Chorioretinopathy. [PDF]

Int Med Case Rep J
Alves Ambrósio J, Pestana Aguiar C, Teixeira PC, Miranda V, Chibante Pedro J, Ruão M.   +5 more
europepmc   +1 more source

Comprehensive analysis of RS1 gene mutations and clinical manifestations in nine unrelated X-linked retinoschisis (XLRS) Chinese families. [PDF]

BMC Ophthalmol
Xing D, Zhao C, Shao Y, Yu R, Cheng Z, Wang L, Cai B, Gong Y, Li Z, Li X.   +9 more
europepmc   +1 more source

Causes of Visual Loss in Uveitis: A Retrospective Study at a Tertiary Referral Centre. [PDF]

Cureus
Al-Roubaie M, Beare N.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Reverse Engineering the Ozurdex Dexamethasone Intravitreal Implant

International Journal of Pharmaceutics, 2023
Ozurdex is a biodegradable implant formulated for sustained-release delivery of the corticosteroid dexamethasone to the posterior segment of the eye. The small, rod-shaped implant is administered directly to the vitreous using a dedicated applicator, and releases drug for up to 6 months after administration.
Xiaoming Xu, Nathaniel A Lynd, Mark A Costello   +2 more
exaly   +3 more sources

Dexamethasone Intravitreal Implant (OZURDEX®) for Macular Edema Secondary to Noninfectious Uveitis: A Review of the Literature

Therapeutic Delivery, 2019
Macular edema (ME) is the leading cause of visual loss in uveitis and may persist long after ocular inflammation has been resolved. Local steroids are the first line treatment for uveitis and uveitic ME.
Horace Massa, Georgios D Panos
exaly   +2 more sources